Actinium Pharmaceuticals, Inc. (ATNM)

1.780.01 (-0.56%)

Actinium Pharmaceuticals, Inc. (ATNM) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

High Bankruptcy RiskBelow Average ESGFair ValuationLow ProfitabilityAdequate Financial HealthInefficient OperationsModerate GrowthLow QualityAdequate Dividend ProfileIndustry Rank: 20.71%Sector Rank: 20.23%

AMEX - Healthcare - Biotechnology | Market Cap: 55.53M | Next Earnings Date: 13 Nov 2025

Day's Range

1.75 - 1.81

52-Week Range

1.03 - 2.41

Volume

122.5K / 297.6K (Avg.)

P/E Ratio | EPS

-1.36 | -1.31

Trending:

ATNM Income Growth Analysis

Compare against a Competitor

None AGEN AVXL RVPH AXSM TRAW

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

-95.21%

Decreased from previous period

Revenue decline while Healthcare median is 0.00%. Seth Klarman would investigate if market share loss is temporary.

Cost of Revenue Growth

31.39%

Cost growth of 31.39% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

-116.81%

Decreased from previous period

Gross profit decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

Gross Margin Ratio Growth

-451.18%

Decreased from previous period

Margin decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

R&D Expenses Growth

6.71%

Increased from previous period

R&D change of 6.71% versus flat Healthcare spending. Walter Schloss would verify adequacy.

G&A Expenses Growth

86.34%

Increased from previous period

G&A change of 86.34% versus flat Healthcare overhead. Walter Schloss would verify efficiency.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Operating Expenses Growth

29.34%

Increased from previous period

Operating expenses growth exceeding 1.5x Healthcare median of 1.65%. Jim Chanos would check for waste.

Total Costs & Expenses Growth

29.34%

Increased from previous period

Total costs growth exceeding 1.5x Healthcare median of 1.70%. Jim Chanos would check for waste.

Interest Expense Growth

-100.00%

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

31.39%

D&A growth exceeding 1.5x Healthcare median of 0.92%. Jim Chanos would check for overinvestment.

EBITDA Growth

-52.58%

Decreased from previous period

EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EBITDA Margin Growth

-3087.14%

Decreased from previous period

EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Income Growth

-52.01%

Decreased from previous period

Operating income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Margin Growth

-3075.40%

Decreased from previous period

Operating margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Other Income/Expenses Growth

137.14%

Increased from previous period

Other expenses change of 137.14% versus flat Healthcare. Walter Schloss would verify control.

Pre-Tax Income Growth

-51.43%

Decreased from previous period

Pre-tax income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Pre-Tax Margin Growth

-3063.27%

Decreased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

100.00%

Tax expense change of 100.00% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

-52.47%

Decreased from previous period

Net income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Net Margin Growth

-3085.00%

Decreased from previous period

Net margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EPS Growth

-43.48%

Decreased from previous period

EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Diluted EPS Growth

-43.48%

Decreased from previous period

Diluted EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Share Count Growth (Basic)

7.17%

Increased from previous period

Share count reduction below 50% of Healthcare median of 0.02%. Jim Chanos would check for issues.

Share Count Growth (Diluted)

7.17%

Increased from previous period

Diluted share reduction below 50% of Healthcare median of 0.01%. Jim Chanos would check for issues.

+ Add New Metric (Coming Soon)

Add more metric or remove existing ones, customize as per your preference, feature coming soon!

Select Chart Metric:

ATNM Income Growth Analysis

Compare against a Competitor

None AGEN AVXL RVPH AXSM TRAW

Revenue Growth

-95.21%

Decreased from previous period

Revenue decline while Healthcare median is 0.00%. Seth Klarman would investigate if market share loss is temporary.

Cost of Revenue Growth

31.39%

Cost growth of 31.39% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

-116.81%

Decreased from previous period

Gross profit decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

Gross Margin Ratio Growth

-451.18%

Decreased from previous period

Margin decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

R&D Expenses Growth

6.71%

Increased from previous period

R&D change of 6.71% versus flat Healthcare spending. Walter Schloss would verify adequacy.

G&A Expenses Growth

86.34%

Increased from previous period

G&A change of 86.34% versus flat Healthcare overhead. Walter Schloss would verify efficiency.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Operating Expenses Growth

29.34%

Increased from previous period

Operating expenses growth exceeding 1.5x Healthcare median of 1.65%. Jim Chanos would check for waste.

Total Costs & Expenses Growth

29.34%

Increased from previous period

Total costs growth exceeding 1.5x Healthcare median of 1.70%. Jim Chanos would check for waste.

Interest Expense Growth

-100.00%

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

31.39%

D&A growth exceeding 1.5x Healthcare median of 0.92%. Jim Chanos would check for overinvestment.

EBITDA Growth

-52.58%

Decreased from previous period

EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EBITDA Margin Growth

-3087.14%

Decreased from previous period

EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Income Growth

-52.01%

Decreased from previous period

Operating income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Margin Growth

-3075.40%

Decreased from previous period

Operating margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Other Income/Expenses Growth

137.14%

Increased from previous period

Other expenses change of 137.14% versus flat Healthcare. Walter Schloss would verify control.

Pre-Tax Income Growth

-51.43%

Decreased from previous period

Pre-tax income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Pre-Tax Margin Growth

-3063.27%

Decreased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

100.00%

Tax expense change of 100.00% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

-52.47%

Decreased from previous period

Net income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Net Margin Growth

-3085.00%

Decreased from previous period

Net margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EPS Growth

-43.48%

Decreased from previous period

EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Diluted EPS Growth

-43.48%

Decreased from previous period

Diluted EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Share Count Growth (Basic)

7.17%

Increased from previous period

Share count reduction below 50% of Healthcare median of 0.02%. Jim Chanos would check for issues.

Share Count Growth (Diluted)

7.17%

Increased from previous period

Diluted share reduction below 50% of Healthcare median of 0.01%. Jim Chanos would check for issues.

+ Add New Metric (Coming Soon)

Add more metric or remove existing ones, customize as per your preference, feature coming soon!

Select Chart Metric: